コンテンツへスキップ
MediciNova, Inc.
　　Message from CEO
　　Our Mission
　　Company Profile
　　Management Team
　　History
　　Ongoing Clinical Studies
　　　　About MN-166 (Ibudilast)
　　　　ALS
　　　　Oncology / Glioblastoma
　　　　DCM
　　　　CIPN
　　　　ARDS / Lung Injury
　　　　About MN-001（Tipelukast)
　　　　NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
　　Press Release
　　Event
　　Media Archive
　　Annual Report
　　SEC filing
　　Stock Quote -TSE
　　Stock Quote -Nasdaq
　　Historical Price Lookup
　　Investment Calculator
　　Analyst Coverage
　　Corporate Governance
　　Information Request
　　Corporate Presentation & Resarch Reports
　　　　Progressive Multiple Sclerosis (Progressive MS)
　　　　Amyotrophic Lateral Sclerosis (ALS)
　　　　Oncology / Glioblastoma
　　　　Substance Dependence and Addiction
　　　　MN-166 (ibudilast) News Articles
　　　　MN-166 (ibudilast) Publications
　　MN-001 Presentation
　　Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001（Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Presentation
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Investor Relations
    • News
    • Events
    • Presentations
    • Stock Quote & Chart
    • TSE Stock Quote
    • Analyst Coverage
    • Equity Research
    • SEC Filings
    • Annual Reports
    • Documents & Charters
    • Email Alerts
  • Contact Us

MediciNova Receives Gene Therapy Milestone Payment

2023.10.042024.08.20
Page Top
medicinova_en
MediciNova, Inc.

関連記事

MN-001

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations

MN-001

MN-001の特発性肺線維症（IPF）を適応とする開発プランの進捗についてのお知らせ

MN-166

MN-166のALS（筋萎縮性側索硬化症）を適応とする特許承認のお知らせ

MN-001

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MN-166

2018/12/7 英国グラスゴーで開催された第 29回 ALS/MNDALS（筋萎縮性側策硬化症/運動神経疾患 ）国際シンポジウムにおいて、 カロライナ・ヘルスケアシテム神経科学研究の神経筋 /ALS・MDAセンター所長のベンジャミ・リックスブル博士が発表した ALSを適応とするMN -166（イブジラスト）の臨床治験に関するプレゼンテーション資料

MediciNova Announces Results of Studies under BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001（Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Presentation
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Investor Relations
      • News
      • Events
      • Presentations
      • Stock Quote & Chart
      • TSE Stock Quote
      • Analyst Coverage
      • Equity Research
      • SEC Filings
      • Annual Reports
      • Documents & Charters
      • Email Alerts
    • Contact Us
  • MediciNova, Inc.